ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 209 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2023. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,457,403 | -24.0% | 366,230 | 0.0% | 0.08% | -24.1% |
| Q1 2023 | $3,233,811 | +15.6% | 366,230 | 0.0% | 0.11% | +4.7% |
| Q4 2022 | $2,797,997 | +49.1% | 366,230 | +39.0% | 0.11% | +37.2% |
| Q3 2022 | $1,876,000 | -21.3% | 263,491 | -10.6% | 0.08% | -13.3% |
| Q2 2022 | $2,384,000 | +18.3% | 294,659 | +103.0% | 0.09% | +45.2% |
| Q1 2022 | $2,015,000 | -37.2% | 145,165 | +26.9% | 0.06% | -30.3% |
| Q4 2021 | $3,211,000 | +15.3% | 114,418 | +39.7% | 0.09% | +14.1% |
| Q3 2021 | $2,784,000 | +15.7% | 81,894 | +39.1% | 0.08% | +39.3% |
| Q2 2021 | $2,406,000 | +30.4% | 58,890 | +28.5% | 0.06% | +36.6% |
| Q1 2021 | $1,845,000 | +3.9% | 45,832 | +52.6% | 0.04% | 0.0% |
| Q4 2020 | $1,776,000 | +21.6% | 30,028 | 0.0% | 0.04% | +13.9% |
| Q3 2020 | $1,460,000 | -38.3% | 30,028 | -38.6% | 0.04% | -33.3% |
| Q2 2020 | $2,365,000 | +90.1% | 48,890 | +9.2% | 0.05% | +74.2% |
| Q1 2020 | $1,244,000 | – | 44,782 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 3,030,434 | $20,334,212 | 13.72% |
| BERYLSON CAPITAL PARTNERS, LLC | 228,000 | $1,529,880 | 4.32% |
| Eagle Health Investments LP | 1,214,860 | $8,151,711 | 1.52% |
| Matrix Capital Management Company, LP | 11,572,590 | $77,652,079 | 0.90% |
| Triatomic Management LP | 121,166 | $813,024 | 0.83% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $201,257,781 | 0.82% |
| Aristotle Atlantic Partners, LLC | 3,104,961 | $20,834,288 | 0.78% |
| Pier Capital, LLC | 737,589 | $4,949,222 | 0.71% |
| ARK Investment Management | 10,453,752 | $70,144,675 | 0.46% |
| Nikko Asset Management Americas, Inc. | 6,384,047 | $42,773,115 | 0.45% |